| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | NS6; CMNS; NCMS; ALPS4; N-ras; NRAS1 |
| WB Predicted band size | 21 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human NRAS |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于NRAS抗体的3篇参考文献示例(内容为虚构，仅作格式参考)：
---
1. **文献名称**: *Development of a High-Affinity Monoclonal Antibody Targeting Oncogenic NRAS Mutations*
**作者**: Smith J, et al.
**摘要**: 本研究报道了一种新型单克隆抗体的开发，该抗体特异性靶向NRAS基因常见的致癌突变(如Q61R和G12V)。通过噬菌体展示技术筛选出高亲和力抗体，并在体外和动物模型中验证其抑制RAS-MAPK信号通路的能力，为NRAS突变肿瘤的靶向治疗提供潜在工具。
---
2. **文献名称**: *NRAS Antibody-Based Immunohistochemistry for Rapid Detection of Metastatic Melanoma*
**作者**: Lee H, et al.
**摘要**: 研究团队开发了一种基于NRAS抗体的免疫组化检测试剂盒，用于快速识别黑色素瘤中NRAS蛋白过表达。通过对比临床样本的基因测序结果，验证了该方法的敏感性和特异性，为临床病理诊断提供了经济高效的替代方案。
---
3. **文献名称**: *Mechanistic Insights into NRAS Antibody Resistance in Colorectal Cancer*
**作者**: Garcia R, et al.
**摘要**: 本文探讨了结直肠癌细胞对NRAS靶向抗体产生耐药的分子机制，发现MEK/ERK信号通路的代偿性激活和肿瘤微环境中的免疫抑制因子是主要驱动因素。研究结果为联合用药策略(如抗体+MEK抑制剂)提供了理论依据。
---
(注：以上文献信息为模拟生成，实际研究中请通过PubMed或Web of Science等平台检索真实文献。)
NRAS antibodies are essential tools in cancer research and diagnostics, targeting the NRAS protein encoded by the NRAS gene. NRAS belongs to the RAS family of small GTPases, which regulate critical cellular processes like proliferation, differentiation, and survival by cycling between active (GTP-bound) and inactive (GDP-bound) states. Mutations in NRAS, particularly at codons 12. 13. or 61. result in constitutive activation of the protein, leading to uncontrolled signaling through pathways such as MAPK and PI3K/AKT. These mutations are frequently observed in cancers like melanoma, acute myeloid leukemia, and colorectal carcinoma.
NRAS antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect NRAS expression and activation status in tumor samples. They help identify patients with NRAS-driven malignancies, guide targeted therapy decisions, and monitor treatment responses. For example, NRAS mutations are associated with resistance to anti-EGFR therapies in colorectal cancer, making these antibodies valuable in clinical stratification.
Despite their utility, targeting NRAS therapeutically remains challenging due to its smooth surface and high affinity for GTP/GDP, limiting direct drug binding. Research using NRAS antibodies focuses on understanding its interaction networks and developing indirect inhibitors. Additionally, cross-reactivity with other RAS isoforms (KRAS, HRAS) must be carefully evaluated to ensure specificity in experimental and diagnostic applications.
×
